Tests a lung rehabilitation program in people with advanced lung cancer

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 70 with advanced non-small-cell lung cancer who can get chemotherapy or tyrosine kinase inhibitors. It tests a pulmonary rehabilitation program.

Age

18 to 70 years

Sex

All sexes can join.

Disease stage

Confirmed advanced non-small-cell lung cancer, in good general condition (ECOG 0-1), with life expectancy of more than 12 weeks.

Earlier treatment

Must be able to receive treatment with chemotherapy or tyrosine kinase inhibitors. A recent electrocardiogram must show no arrhythmia.

Main reasons for not taking part

• Brain metastasis that causes symptoms
• Pain that is not controlled (Visual Analog Scale above 5)
• High blood pressure that is not controlled (above 140/100mmHg)
• Regular moderate to intense exercise at least 3 days a week
• Not living in Mexico City or unable to attend therapy sessions

The registry criteria, word for word

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

• Are you between 18 and 70 years old?YesNo

What the trial wants to find out

Lung cancer (LC) is usually diagnosed in advanced stages and continues to be the leading cause of cancer related deaths worldwide. Cancer cachexia are frequent among patients with LC affecting up to 80% of patients with advanced stage disease, and it has been related with higher risk of complications, length of hospital stay, and worst overall survival. During cancer cachexia, both muscle and fat mass can be wasted, however, the loss of muscle mass has been associated to higher treatment related toxicity, loss of functional status, shorter progression free survival and overall survival in different types of cancer under various treatments. Hence, preservation of muscle mass and function should be an important focus of the multidisciplinary treatment of patients with LC.

The 2 groups in the trial

• Intervention GroupTreatment being tested

  Patients in the IG will be scheduled to receive Pulmonary Rehabilitation: 12 sessions (60 minutes approximately) over a period of 4-6 weeks (2-3 session/week). Sessions will progress as patients tolerance to exercise and will include breathing techniques, resistance training on ergometer and treadmill.

  Treatment: Pulmonary rehabilitation

• Control GroupNo study treatment, for comparison

  CG will receive information and recommendations on physical activity